Chlamydia Infection Diagnostics and Therapeutics Market Research Report

Posted by Aman Jaiswar on June 12th, 2019

The chlamydia infection diagnostics and therapeutics market unveils high potential owing to the rapidly rising patient pool and vast untapped opportunities, especially in developing economies across regions such as Asia Pacific and Latin America. The market expected to exhibit healthy growth in the near future due to the increasing focus on treatment of sexually transmitted diseases globally. There is a need for enhanced techniques of diagnosis of pelvic inflammatory disease and for signs of chlamydial infection that expects women at high threat of tubal damage. Chlamydia trachomatis is the most commonly reported sexually transmitted infection in the world. The rate of reported chlamydia infection diagnoses continues to increase.

Transparency Market Research estimates that the global Chlamydia Infection diagnostics and therapeutics market will expand at a robust CAGR of 6.0% over the forecast period between 2017 and 2025.

Request to View Sample of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8212

In terms of product type, the global chlamydia infection diagnostics market has been segmented in the report into nucleic acid amplification tests (NAATs), and direct fluorescent tests. Of these, the segment of nucleic acid amplification is expected to steadily expand, albeit at a moderate CAGR, over the report’s forecast period. The segment will be closely followed by the direct fluorescent in 2016 and through the forecast period. The continuous rise in the number of diagnosed cases of chlamydia is due to the preference shift towards more the extensive diagnostic tests and testing of asymptomatic people with greater sensitivity that is shift from culture based methods to nucleic acid amplification tests (NAATs)

Chlamydia infection therapeutics market is segmented by product type into macrolides, quinolones, sulfonamides, tetracycline, Aminopenicillins. Physician prescription preference for antibiotics such as macrolides and tetracycline is driving the growth of chlamydia infection therapeutics market. The segment of macrolides is expected to expand at a promising pace during the report’s forecast period. This is followed by the direct fluorescent sub-segment, which contributed for second highest share in the global Chlamydia Infection diagnostics market in 2016.